Here is an abstract from an article in the academic journal, Science, Public Health Policy, and the Law, which even based upon the data at that time expressed scepticism about a mass vaccination program. “The present assessment raises the question of whether it could be necessary to rethink vaccination policies. Given the high number of serious side effects already reported, the current political trend of vaccinating children who are at very low risk of suffering from COVID-19 in the first place must be reconsidered.” Further evidence covered at this blog each day well supports that conclusion, and beyond.
“Science, Public Health Policy, and the Law Volume 3:87-99 August, 2021 Clinical and Translational Research An Institute for Pure and Applied Knowledge (IPAK) Public Health Policy Initiative (PHPI) The Safety of COVID-19 Vaccinations — Should We Rethink the Policy? Harald Walach, 1* Rainer J. Klement, 2 and Wouter Aukema3 Abstract Background: COVID-19 vaccines have had expedited reviews without sufficient safety data. We wanted to compare risks and benefits. Methods: We calculated the Number Needed to Vaccinate (NNTV) to prevent one death from a large Israeli field study. We accessed the Adverse Drug Reactions database of the Dutch National Register (Lareb) to extract the number of cases reporting severe side-effects and the number of cases reporting fatal side-effects. Results: The NNTV is between 200 and 700 to prevent one case of COVID-19 for the mRNA vaccine marketed by Pfizer. NNTV to prevent one death is between 9,000 and 100,000 (95% confidence interval), with 16,000 as a point estimate. We observed strong variability in the number of Individual Case Safety Reports (ICSRs) per 100,000 vaccine doses across all EU member states. The estimate for the number of ICSRs per 100,000 vaccinations derived from the Lareb database was approximately 700. Among those, there were 16 serious ICSRs, and the number of ICSRs reporting fatal side-effects was at 4.11/100,000 vaccinations. Thus, for 6 (95% CI 2–11) deaths prevented by vaccination, there were approximately 4 deaths reported to Dutch Lareb that occurred after vaccination, yielding a potential risk/benefit ratio of 2:3. Conclusion: Although causality between ICSRs and vaccination has not been established, these data indicate a lack of clear benefit, which should cause governments to rethink their vaccination policy.
5 Conclusion The present assessment raises the question of whether it could be necessary to rethink vaccination policies. Given the high number of serious side effects already reported, the current political trend of vaccinating children who are at very low risk of suffering from COVID-19 in the first place must be reconsidered. It is also vital that these products be made accessible only to those who are willing to use them and to accept potential risks that come with the products. In our view, the EMA and national authorities should begin a review into the safety database of COVID-19 vaccines, and governments should carefully re-consider their policies in the light of these data. Ideally, independent scientists should be permitted to carry out thorough case reviews of the very severe cases, so that there can be evidence-based recommendations on who is likely to benefit from a SARS-CoV-2 vaccination and who is in danger of suffering from side effects. In addition, because SARS-CoV-2 is a BSL2 pathogen, autopsies should be carried out on every body. Currently, our estimates show that we must accept 4 reports of fatal and 16 reports of serious side effect per 100,000 vaccinations in order to save the lives of 8 to 33 people. Bluntly, we would have to accept that 2 people might die to save the lives of three to 15 people. This ratio might improve as more time after vaccination passes, but this needs to be studied diligently.”